Aug 7, 2025, 14:24
New Treatment Option for H3 K27M-Mutant Glioma Treatment – Jazz Pharmaceuticals
Jazz Pharmaceuticals shared a post on LinkedIn:
“H3 K27M-mutant diffuse midline glioma is an ultra-rare, aggressive brain cancer that has historically been marked by limited treatment options and poor prognoses.
Today’s approval represents an important advancement for patients and caregivers impacted by this difficult-to-treat disease by offering them a new treatment option.
The collaborative efforts that culminated in this meaningful achievement showcase our dedication to innovation to help meet the needs of patients and their families.”
More posts featuring Jazz Pharmaceuticals on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 7, 2025, 13:56
Aug 7, 2025, 13:43
Aug 7, 2025, 12:39
Aug 7, 2025, 12:37
Aug 7, 2025, 12:28